Search Results - manuel+penichet

2 Results Sort By:
Novel IGE Antibodies for the Therapy of Cancer (UCLA Case No. 2021-043)
Researchers at UCLA’s David Geffen School of Medicine have designed three novel antibodies of the IgE class targeting antigens CD138, CD38, and transferrin receptor 1 (TfR1/CD71): cancer antigens present in various hematopoietic and/or solid tumors. There are several advantages of IgE class antibodies compared to the commonly used IgG class in...
Published: 6/1/2026   |   Updated: 9/10/2021   |   Inventor(s): Manuel Penichet, Pierre Candelaria, Miguel Nava, Tracy Daniels-Wells
Keywords(s): Cancer, Immunoglobulin G
Category(s): Platforms > Drug Delivery > Peptide Base, Therapeutics > Hematology
Anti-PSA (Prostate-Specific Antigen) IgG (UCLA Case No. 2014-845)
Anti-PSA IgGSUMMARYResearchers at UCLA have developed chimeric IgG specific for prostate-specific antigen (PSA) in human and mouse cells.BACKGROUNDProstate-specific antigen (PSA) is a substance made by cells in the prostate gland. Physicians use high PSA levels (above 4 nanograms per milliliter) as a blood biomarker for prostate cancer. Given this,...
Published: 6/26/2025   |   Updated: 8/28/2019   |   Inventor(s): Manuel Penichet, Tracy Daniels-Wells, Gustavo Helguera
Keywords(s): Antibodies, Diagnostic Markers & Platforms, Diagnostic Platform Technologies (E.G. Microfluidics), Life Science Research Tools, Oncology
Category(s): Life Science Research Tools, Life Science Research Tools > Antibodies, Diagnostic Markers, Platforms > Diagnostic Platform Technologies, Therapeutics > Oncology